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Recently, loss of beta-cell-specific traits has been
proposed as an early cause of beta cell failure in dia-
betes. However, the molecular mechanisms that
underlie the loss of beta cell features remain unclear.
Here, we identify an Nkx6.1-controlled gene regula-
tory network as essential for maintaining the
functional and molecular traits of mature beta cells.
Conditional Nkx6.1 inactivation in adult mice caused
rapid-onset diabetes and hypoinsulinemia. Genome-
wide analysis of Nkx6.1-regulated genes and func-
tional assays further revealed a critical role for
Nkx6.1 in the control of insulin biosynthesis, insulin
secretion, and beta cell proliferation. Over time,
Nkx6.1-deficient beta cells acquired molecular char-
acteristics of delta cells, revealing a molecular link
between impaired beta cell functional properties
and loss of cell identity. Given that Nkx6.1 levels
are reduced in human type 2 diabetic beta cells,
our study lends support to the concept that loss of
beta cell features could contribute to the pathogen-
esis of diabetes.
INTRODUCTION
Type 2 diabetes mellitus (T2D) is characterized by reduced insu-
lin sensitivity of insulin target tissues and impaired insulin secre-
tion by pancreatic beta cells. Although both of these factors play
a role, genetic studies suggest that the ability of beta cells to
respond to metabolic stressors is the predominant factor in
determining the predisposition to T2D (Muoio and Newgard,
2008).
In T2D, beta cells exhibit an impaired capacity to compensate
for increased insulin demand (Cerasi and Luft, 1967), a defect
that has been ascribed to both inadequate cellular capacity to
secrete insulin (Hosker et al., 1989) and beta cell death (Butler
et al., 2003). Among the earliest defects observed in T2D patients
is a reduced ability of beta cells to secrete insulin in response to
elevated blood glucose levels (Hosker et al., 1989). This impair-
ment in glucose-stimulated insulin secretion has been attributed
to defects in glucose sensing (Froguel et al., 1992), mitochondrial1262 Cell Reports 4, 1262–1275, September 26, 2013 ª2013 The Audysfunction (Supale et al., 2012), and oxidative stress (Robert-
son, 2004). Thus, mounting evidence suggests that defects in
multiple cellular processes can compromise beta cell function
and could be a factor in T2D development. Furthermore, hyper-
glycemia has been shown to impair the expression of genes that
are important for beta cell identity (Jonas et al., 1999). More
recently, Talchai et al. (2012) described a loss of beta cell fea-
tures, characterized by a decline in insulin production, acquisi-
tion of progenitor-like characteristics, and fate conversion into
other endocrine cell types in mouse models of T2D, suggesting
that loss of the differentiated beta cell state also contributes to
beta cell failure in T2D. However, it is currently unknown whether
the loss of beta cell functional properties (namely, regulated
insulin secretion) and loss of beta cell identity are linked during
T2D progression. A simultaneous loss of beta cell function and
identity could be explained by reduced expression of a central
transcriptional regulator controlling genes involved in both
processes.
Several lines of evidence suggest that the beta-cell-enriched
transcription factor Nkx6.1 could have a role in T2D. First,
genome-wide association studies suggest that variants of
Nkx6.1 associate with T2D (Yokoi et al., 2006). Second,
decreased Nkx6.1 expression has been shown to accompany
the development of T2D in rodents and humans (Guo et al.,
2013; Talchai et al., 2012). Third, in vitro studies in beta cell lines
and isolated islets suggest a possible role for Nkx6.1 in the regu-
lation of glucose-stimulated insulin secretion as well as beta cell
proliferation (Schisler et al., 2005, 2008). Additionally, we
recently showed that Nkx6.1 is necessary and sufficient to
confer beta cell identity to differentiating endocrine precursors
in the embryo (Schaffer et al., 2013), raising the possibility that
Nkx6.1 could also help maintain the differentiated state of adult
beta cells. Together, these findings suggest that Nkx6.1 may be
a regulator of beta cell function and identity in adult animals.
To explore the role of Nkx6.1 in mature beta cells, we ablated
Nkx6.1 specifically in beta cells of adult mice and identified
Nkx6.1 target genes in beta cells by combining gene-expression
profiling and chromatin immunoprecipitation with massively par-
allel sequencing (ChIP-seq). We found that loss of Nkx6.1
caused rapid-onset diabetes due to defects in insulin biosyn-
thesis and secretion. The observed loss in insulin production
and beta cell functional properties was later accompanied by
ectopic activation of delta cell genes in beta cells. Thus, by im-
pairing beta cell function and destabilizing beta cell identity,thors
reduced Nkx6.1 levels, as seen in T2D, could contribute to the
pathogenesis of T2D.
RESULTS
Loss of Nkx6.1 in Mature Beta Cells Causes Diabetes
and Reduced Insulin Production
To examine Nkx6.1 function in mature beta cells in vivo, we
conditionally inactivated Nkx6.1 in islet cells of adult mice by
triggering recombination of an Nkx6.1flox (Nkx6.1fl) allele with
the tamoxifen-inducible Pdx1-CreERTM transgene. Pdx1-
CreERTM;Nkx6.1fl/ and Pdx1-CreERTM;Nkx6.1fl/+ mice were in-
jected with tamoxifen between 4 and 6 weeks of age to produce
Nkx6.1Dadultb and control mice, respectively (Figures 1A and 1B).
Quantitative RT-PCR (qRT-PCR) and immunofluorescence
staining for Nkx6.1 demonstrated efficient recombination of the
Nkx6.1fl allele in beta cells (Figures 1C, 1I, and 1J).
To determine whether Nkx6.1 deletion affects beta cell func-
tion, we conducted glucose tolerance tests and measured blood
glucose levels. Glucose tolerance tests performed 1 week after
the last tamoxifen injection revealed elevated fasting blood
glucose levels and glucose intolerance in male Nkx6.1Dadultb
mice when compared with tamoxifen-treated and non-tamox-
ifen-treated control mice (Figure 1D). Likewise, blood glucose
levels were significantly elevated in Nkx6.1Dadultb mice fed ad
libitum, with levels reaching near 500 mg/dl within 8 weeks after
the last tamoxifen injection (Figure 1E). Female Nkx6.1Dadultb
mice also became diabetic, but the phenotype developed
slightly later and was less severe than in males (Figures S1A–
S1C). Thus, loss of Nkx6.1 in adult beta cells causes rapid devel-
opment of diabetes.
To investigate whether diabetes in Nkx6.1Dadultb mice is
caused by insulin insufficiency, we measured plasma insulin
levels after glucose administration. As expected, control mice re-
sponded to a glucose bolus with a rapid increase in plasma insu-
lin levels within 5 min of glucose administration (Figure 1F). By
contrast, insulin levels did not increase in Nkx6.1Dadultb mice
and blood glucose levels were significantly higher than in control
mice (Figures 1F and 1G). A striking reduction in pancreatic insu-
lin content inNkx6.1Dadultbmice (Figure 1H) further demonstrated
decreased overall pancreatic insulin production. To determine
whether the reduction in pancreatic insulin levels in Nkx6.1Dadultb
mice is a result of beta cell loss, we next examined beta cell sur-
vival and quantified beta cell mass. Nkx6.1Dadultb mice did not
show increased beta cell apoptosis (Figures S2A–S2D) or
reduced mass of endocrine or beta cells (Figures S2E–S2H),
suggesting that diabetes in Nkx6.1Dadultb mice is caused by
decreased insulin biosynthesis rather than beta cell loss. Consis-
tent with a possible defect in the cellular production of insulin, the
insulin fluorescence signal was dramatically reduced in Nkx6.1-
deficient beta cells (Figures 1I and 1J). Notably, reduced insulin
production did not appear to be accompanied by a change in
endocrine cell type identity, as insulin+ cells in Nkx6.1Dadultb
mice did not coexpress other pancreatic hormones (Figures
S2I–S2N). These data suggest that diabetes following Nkx6.1
inactivation is initially caused at least in part by loss of insulin
production, but not by cell death or conversion into other endo-
crine cell types.Cell ReNkx6.1 Directly Regulates Islet Transcription Factors
and Genes Involved in Glucose Metabolism and Insulin
Biosynthesis
To more globally understand how loss of Nkx6.1 impacts beta
cell gene expression, and to identify molecular pathways that
are immediately affected following Nkx6.1 inactivation, we next
conducted transcriptional profiling of Nkx6.1Dadultb and control
islets 3 days after completion of tamoxifen-inducedNkx6.1 abla-
tion (Figure 2A). At this time point, Nkx6.1Dadultb mice were only
mildly glucose intolerant and blood glucose levels of mice fed
ad libitum were still below 250 mg/dl (Figures S3A and S3B). A
comparison of gene-expression profiles between Nkx6.1Dadultb
and control islets revealed significant differences in the expres-
sion of 1,455 genes (false discovery rate [FDR] < 0.01 and fold
change [FC] > 1.5; Table S1), of which 887 were upregulated
and 568 were downregulated. To define the cellular processes
affected by Nkx6.1 inactivation, we performed Gene Ontology
(GO) analysis of the differentially expressed genes. Consistent
with the diabetic phenotype, Nkx6.1-regulated genes showed
association with biological processes that are critical for beta
cell function, such as ion transport, regulation of secretion,
oxidation reduction, insulin secretion, and hexose biosynthesis
(Figure 2B). These data suggest that reduced insulin production
may not be the only cause of hyperglycemia following Nkx6.1
deletion, and that simultaneous impairment of multiple pro-
cesses required for proper beta cell function could contribute
to the development of diabetes in Nkx6.1Dadultb mice.
To distinguish between direct transcriptional target genes of
Nkx6.1 and genes indirectly affected by Nkx6.1 inactivation,
we performed ChIP-seq for Nkx6.1 on primary mouse islets
to identify Nkx6.1-occupied genes. We detected a total of
6,771 Nkx6.1 binding regions throughout the murine genome
(FDR < 0.001; Table S2), 4,066 of which were near genes or in-
tronic (Figure 2C). De novo motif analysis revealed a TAAT
core motif and two flanking nucleotides on each side as the
sequence motif preferentially occupied by Nkx6.1 (Figure 2D).
Notably, the TAAT core of the Nkx6.1 de novo binding motif
was previously identified by an in vitro electrophoretic mobility
shift assay (Jørgensen et al., 1999). The TAAT motif is shared
among many homeodomain transcription factors (Wilson et al.,
1996), demonstrating binding of Nkx6.1 to the core homeodo-
main-binding motif.
Next, to determine the overlap between the genes occupied
by Nkx6.1 in beta cells and genes whose expression is affected
by Nkx6.1 loss, we analyzed which of the 1,988 Nkx6.1 binding
sites within 10 kb of a transcriptional start site were associated
with genes significantly regulated in Nkx6.1-deficient islets. Sur-
prisingly, only 8% of Nkx6.1-occupied genes (135/1,818) were
also regulated by Nkx6.1 (Figure 2E; Table S3). Similarly, of the
1,455 genes with statistically significant changes in expression,
only 9% were bound by Nkx6.1 (Figure 2E), indicating that only
a fraction of the genes affected by Nkx6.1 inactivation depend
directly on transcriptional input by Nkx6.1. Statistical analysis
using hypergeometric distribution (Bhinge et al., 2007) revealed
that this overlap between Nkx6.1-bound and -regulated genes
was still significantly greater than randomly expected (p <
0.05). Interestingly, an equal percentage of Nkx6.1-bound and
-regulated genes were upregulated as were downregulatedports 4, 1262–1275, September 26, 2013 ª2013 The Authors 1263
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Figure 1. Deletion of Nkx6.1 in Adult Beta Cells Results in Diabetes and Loss of Pancreatic Insulin
(A) Schematic of alleles and transgenes used to inactivate Nkx6.1 in adult beta cells. Rectangles: coding sequences; triangles: loxP sites.
(B) Schematic of the experimental design. wks, weeks.
(C) qRT-PCR analysis of isolated islets shows a significant reduction of Nkx6.1 in Nkx6.1Dadultb mice (n = 3).
(D) Intraperitoneal glucose tolerance test reveals glucose intolerance in male Nkx6.1Dadultb mice compared with noninjected and tamoxifen (TM)-treated control
mice at 7 weeks (n = 6). Solid lines: post-TM treatment; dashed lines: without TM treatment.
(E) Blood glucose measurements of mice fed ad libitum show diabetes in male Nkx6.1Dadultb mice (n = 6).
(F and G) Nkx6.1Dadultb mice have lower plasma insulin levels and elevated blood glucose after a glucose stimulus compared with control mice (n = 6).
(legend continued on next page)
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(Figures 2F and 2G), suggesting that Nkx6.1 can act as both a
transcriptional repressor and activator.
Nkx6.1 was found to directly regulate various critical beta cell
genes, including genes involved in glucose uptake and meta-
bolism (Slc2a2 [Glut2], Pcx, and G6pc2) and insulin processing
(Ero1lb and Slc30a8), as well as transcriptional regulators with
known roles in islet development and/or beta cell function
(MafA, Rfx6, Mnx1, and Tle3; Figure 2E). These results suggest
that Nkx6.1 exerts its function by transcriptionally regulating me-
diators of multiple beta cell processes.
The Insulin Secretory Response Is Impaired afterNkx6.1
Inactivation
The insulin secretory response of beta cells is regulated by the
coupling of glucose metabolism to insulin secretion (Muoio and
Newgard, 2008). Glycolysis results in an increase in the ATP:ADP
ratio, which serves as the key trigger for closure of ATP-sensitive
potassium channels (KATP channels), ultimately stimulating cal-
cium influx and insulin secretion. Because Nkx6.1 directly regu-
lates the glucose metabolic genes Glut2, Pcx, and G6pc2 (Table
S1; Figures 3A–3C), we hypothesized that glucose uptake,
glycolytic flux, and energy production could be impaired in
Nkx6.1-deficient beta cells. Supporting the conclusion that the
downregulation of Glut2 is physiologically significant, we found
that Nkx6.1Dadultbmice were resistant to streptozotocin-induced
beta cell death (data not shown), which depends on Glut2-medi-
ated uptake of streptozotocin (Schnedl et al., 1994).
To investigate whether the changes in expression of glucose
metabolic genes are associated with defects in energy produc-
tion, we stained pancreata for phospho-AMP kinase (p-AMPK),
a sensitive indicator of cellular energy depletion (low ATP:AMP
ratio; Porat et al., 2011). Nkx6.1Dadultb islets displayed strikingly
more intense p-AMPK staining than control islets (Figures 3D–
3E0), indicating that loss of Nkx6.1 causes reduced glycolytic
flux and energy stress. Further supporting this conclusion, in-
tracellular ATP content was also significantly decreased in
Nkx6.1Dadultb islets (Figure 3F). We conclude that despite
increased blood glucose levels, Nkx6.1 deficiency results in
energy-depleted beta cells. Since energy depletion has been
shown to impair insulin secretion and cause diabetes in mice
(Piston et al., 1999; Porat et al., 2011; Terauchi et al., 1995),
the defect in energy production in Nkx6.1Dadultb mice could
lead to a severely impaired insulin secretory response.
In addition to affecting ATP production, Nkx6.1 deletion also
led to reduced expression of Sytl4, a vesicle-associated protein
that has been implicated in the modulation of insulin secretion
(Gomi et al., 2005), as well as Ucn3 and Glp1r (Figures 3G–3I),
which are involved in peptide-mediated potentiation of insulin
secretion (Li et al., 2007; Preitner et al., 2004). These changes
in gene expression suggest that Nkx6.1 also has glucose-meta-
bolism-independent roles in insulin secretion. Notably, core
components of the stimulus-secretion-coupling mechanism
(e.g., Abcc8, Kcnj11, and Cacna1c) and genes encoding pro-(H) Pancreatic insulin content normalized to protein concentration is reduced in
(I and J) Immunofluorescence staining reveals almost complete absence of Nkx6.1
represents 20 mm. Ins, insulin. Data are shown as mean ± SEM. *p < 0.05, **p <
See also Figures S1 and S2.
Cell Reteins important for vesicle docking (e.g., Pclo and Noc2) were
normally expressed in Nkx6.1-deficient islets (Figure 3G).
To directly test whether the observed changes in gene
expression affect insulin secretion at a functional level, we per-
formed in vitro glucose-stimulated insulin secretion (GSIS) as-
says on isolated islets from Nkx6.1Dadultb and control mice. To
account for the decreased insulin content of Nkx6.1-deficient
beta cells, we calculated insulin secretion as a percentage of
total islet insulin content. Islets from Nkx6.1Dadultbmice secreted
less of their total insulin than the control islets under conditions
of basal (2.7 mM) and high (16.7 mM) glucose concentrations
(Figure 3J), showing that insulin secretion is impaired after
Nkx6.1 deletion. However, stimulation of secretion by glucose
appeared to be unaffected by Nkx6.1 deletion, as there was a
similar increase in insulin secretion in Nkx6.1Dadultb and control
islets under both low- and high-glucose conditions (3.75-fold in-
crease between 2.7 mM and 16.7 mM glucose in Nkx6.1Dadultb
islets versus a 3.06-fold increase in control islets). The insulin
secretory pattern of Nkx6.1Dadultb islets is highly similar to the
pattern observed in Glut2-deficient islets (Guillam et al.,
2000), suggesting that loss of Glut2 in Nkx6.1Dadultb beta cells
makes a major contribution to the insulin secretory defect.
Notably, additional defects downstream of KATP channel-medi-
ated membrane depolarization also appear to exist, as insulin
secretion in Nkx6.1-deficient islets was also reduced in
response to membrane depolarization and calcium influx
(30 mM KCl and 2 mM Bay K8644, respectively; Figure 3J).
Together, these results imply that impaired insulin secretion is
a major contributor to the diabetic phenotype of Nkx6.1Dadultb
mice.
Decreased Beta Cell Proliferation in Nkx6.1Dadultb Mice
It has been suggested that glycolytic flux and ATP production
serve as a trigger for beta cell replication (Porat et al., 2011).
Specifically, glucose metabolism is thought to control beta
cell proliferation by regulating expression of Cyclin D2 (Ccnd2)
(Salpeter et al., 2010, 2011), which is a critical regulator of
beta cell mass in mice (Georgia and Bhushan, 2004; Kushner
et al., 2005). Since Nkx6.1-deficient beta cells have defects in
energy production, we examined whether Nkx6.1 deletion af-
fects Ccnd2 messenger RNA (mRNA) levels. We found that
Ccnd2 mRNA levels were indeed decreased in Nkx6.1Dadultb
islets (Table S1; Figure 4A). Strikingly, Nkx6.1 inactivation spe-
cifically affected Ccnd2, whereas the mRNA levels of other
cyclins were unaffected (Table S1; Figure 4A). Immunofluores-
cence staining (Figures 4B–4C0) and western blot analysis (Fig-
ure 4D) further demonstrated significantly reduced Cyclin D2
protein levels in beta cells of Nkx6.1Dadultb mice. Similar to the
phenotype of Ccnd2 null mutant mice (Georgia and Bhushan,
2004; Kushner et al., 2005), Nkx6.1-deficient beta cells ex-
hibited a reduction in the number of beta cells expressing the
proliferation marker Ki67 (Figure 4E), showing that beta cell pro-
liferation is impaired after Nkx6.1 inactivation. Notably, Nkx6.1Nkx6.1Dadultb mice (n = 6).
and reduced insulin expression inNkx6.1Dadultbmice at 7 weeks. The scale bar
0.01, ***p < 0.001.
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Figure 2. Nkx6.1 Regulates Important Beta Cell Genes
(A) Schematic of experimental design for microarray analysis.
(B) GO analysis of differentially expressed genes as identified by cDNA microarray analysis of Nkx6.1Dadultb and control islets.
(C) Distribution of Nkx6.1 binding peaks from ChIP-seq analysis within the genome.
(D) De novo motif analysis of Nkx6.1 binding peaks identifies a consensus Nkx6.1 binding motif.
(E) Venn diagram of genes bound and regulated by Nkx6.1 in mature islets.
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(A) qRT-PCR analysis of islets from Nkx6.1Dadultb and control mice at 6 weeks for genes involved in glycolytic flux (n = 3).
(B–E’) Immunofluorescence staining of pancreata from Nkx6.1Dadultb and control mice at 6 weeks.
(F) ATP measurement in islets from Nkx6.1Dadultb and control mice at 6 weeks (n = 8).
(G) qRT-PCR analysis of islets from Nkx6.1Dadultb and control mice at 6 weeks for genes involved in insulin secretion (n = 3).
(H and I) Immunofluorescence staining for Ucn3 in Nkx6.1Dadultb and control pancreata at 6 weeks.
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Figure 4. Nkx6.1 Maintains Cyclin D2 Expression and Beta Cell Proliferative Capacity through the Regulation of Glucose Uptake
(A) qRT-PCR analysis of islets shows a decrease in Ccnd2 expression in Nkx6.1Dadultb compared with control mice at 6 weeks (n = 3).
(B–C’) Immunofluorescence staining for insulin and Cyclin D2 shows a decrease in Cyclin D2 expression in beta cells ofNkx6.1Dadultbmice at 6 weeks. (B’) and (C’)
are higher-magnification images of (B) and (C), respectively. White arrowheads point to Cyclin D2high cells.
(D) Immunoblot analysis of whole-cell islet lysates confirms reduced Cyclin D2 expression in Nkx6.1Dadultb mice.
(E) Quantification of the percentage of insulin+ cells expressing Ki67 shows decreased beta cell proliferation in Nkx6.1Dadultb mice at 6 weeks (n = 3).
(F) qRT-PCR analysis of genes with decreased expression in islets from Nkx6.1Dadultb mice after adenoviral infection of Nkx6.1Dadultb islets with Ad-CMV-Glut2
(Ad-Glut2) and control islets withAd-CMV-b-gal (Ad-b-gal) (n = 3). Ad-Glut2 restoresCcnd2 expression to levels observed in control islets infected with Ad-b-gal.
(legend continued on next page)
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did not occupy Ccnd2 regulatory sequences (Table S2), sug-
gesting that the regulation of Ccnd2 by Nkx6.1 could be
indirect.
Restoring Glucose Import Reinstates Ccnd2 Expression
in Nkx6.1Dadultb Islets
To explore whether limited glucose uptake capacity due to loss
of Glut2 could be the main cause of reduced Ccnd2 expression
in Nkx6.1-deficient islets, we investigated whether restoring
Glut2-mediated glucose import could increase Ccnd2 levels
after Nkx6.1 inactivation. To examine this, we reconstituted
Glut2 expression in Nkx6.1Dadultb islets using an adenovirus
containing Glut2 complementary DNA (cDNA; Ad-Glut2), which
resulted in a 25-fold increase in Glut2 mRNA levels compared
with Ad-b-gal-treated control islets, and restored Glut2 protein
expression (Figures 4F and S4). Glut2 reconstitution increased
Ccnd2 expression to the levels of the control islets, whereas
expression of other Nkx6.1-regulated genes remained signifi-
cantly reduced (Figure 4F). Glut2 reconstitution in Nkx6.1Dadultb
islets also restored the number of insulin+ cells expressing Ki67
to control values (Figure 4G), indicating that Glut2 reexpression
rescues the proliferation defect. These findings demonstrate
that Ccnd2 expression does not depend on direct transcrip-
tional input from Nkx6.1, and that Nkx6.1 controls Ccnd2
and beta cell proliferation indirectly by regulating glucose
import.
Consistent with the notion that glycolytic flux regulates Ccnd2
expression via the stimulus-secretion-coupling pathway (Sal-
peter et al., 2010, 2011), increasing calcium influx by treating
islets with the L-type-dependent calcium channel opener Bay
K8644 similarly restoredCcnd2 expression inNkx6.1Dadultb islets
(Figure 4H). Significantly, Bay K8644 administration to mice
increased the number of insulin+ cells expressing Ki67 to control
values (Figure 4I), providing in vivo evidence that beta cell prolif-
eration can be rescued by stimulating calcium influx. In contrast,
culture of Nkx6.1-deficient islets in the presence of an activator
for the rate-limiting enzyme of glycolysis, glucokinase, or the
beta cell mitogen, insulin (Paris et al., 2003), failed to restore
Ccnd2 expression (Figures 4J and 4K; also compare with Fig-
ure 4A). These findings illustrate that the proliferative capacity
of beta cells is coupled to glucose metabolism and that Nkx6.1
controls this process by regulating Glut2 expression. Because
beta cells have a low turnover rate in adult mice (Teta et al.,
2005), the observed reduction in beta cell proliferation did not
result in decreased beta cell mass in our acute Nkx6.1 deletion
model (Figures S2G and S2H). However, the decreased prolifer-
ative capacity could become metabolically relevant when beta
cells need to undergo adaptive expansion under conditions of
increased insulin demand.(G) Quantification of the percentage of insulin+ cells expressing Ki67 after infectio
Glut2 restores the number of Ki67+ beta cells in Nkx6.1Dadultb islets to control va
(H) qRT-PCR analysis after a 3 hr treatment of Nkx6.1Dadultb islets with the calciu
(I) Quantification of the percentage of insulin+ cells expressing Ki67 after injectio
vehicle (n = 3). Stimulation of calcium influx restores Ccnd2 expression and beta
(J and K) qRT-PCR analysis of islets from Nkx6.1Dadultb mice treated with 10 mM
vehicle (n = 3). The scale bar represents 20 mm. Data are shown as mean ± SEM
See also Figure S4.
Cell ReNkx6.1Dadultb Mice Have Posttranscriptional Defects in
Insulin Biosynthesis
Our gene expression and ChIP-seq analysis revealed that
Nkx6.1 also controlled genes required for insulin biosynthesis,
which could explain the reduction in pancreatic insulin levels in
Nkx6.1Dadultbmice. Most notably, expression of the T2D-associ-
ated zinc transporter Slc30a8, the oxidoreductase Ero1lb, and
the proinsulin-to-insulin convertase Pcsk1 (PC1) was severely
reduced in Nkx6.1-deficient beta cells (Table S1; Figures 5A–
5E). These proteins have established roles in insulin processing
and/or maturation of insulin secretory vesicles (Bellomo et al.,
2011; Zhu et al., 2002; Zito et al., 2010), implying a role for
Nkx6.1 in multiple aspects of the insulin biosynthesis pathway.
Notably, the finding that Ins1 and Ins2 mRNA levels were not
significantly changed (Table S1; Figure 5F) suggests that
reduced insulin production in Nkx6.1Dadultb mice is mainly
caused by posttranscriptional defects in insulin biosynthesis.
To further define which steps in insulin biosynthesis are affected
by Nkx6.1 inactivation, we measured pancreatic proinsulin con-
tent and calculated the insulin-to-proinsulin ratio in Nkx6.1Dadultb
islets. Compared with control mice, pancreatic proinsulin levels
and the ratio of insulin to proinsulin were significantly reduced
in Nkx6.1Dadultb mice (Figures 5G and 5H). Although the defect
in proinsulin-to-insulin processing was expected based on the
observed decrease in Slc30a8, Ero1lb, and Pcsk1 expression,
it is less clear why loss of Nkx6.1 impairs proinsulin biosynthesis.
Because glucose is a direct stimulator of proinsulin translation
(Wicksteed et al., 2003), we examined whether decreased Glut2
expression inNkx6.1Dadultbmice limits the intracellular availability
of glucose and in turn reduces proinsulin production. However,
restoring Glut2 expression in Nkx6.1Dadultb-dispersed islets had
no effect on proinsulin or insulin levels (Figures S5A and S5B),
suggesting that reduced expression of insulin biosynthetic en-
zymes, rather than glucose import, limits proinsulin synthesis in
Nkx6.1Dadultb mice.
To determine whether the defect in insulin biosynthesis affects
the formation of insulin secretory vesicles, we examined secre-
tory vesicle numbers and morphology in beta cells from
Nkx6.1Dadultb and control mice. According to the guidelines
established by Pictet et al. (1972), secretory vesicles were
considered immature if they had a homogeneous light gray
appearance similar to the electron density of the cytoplasm, or
mature if the vesicles contained an electron-dense granule
darker than the density of the cytoplasm. Transmission electron
microscopy (TEM) showed that the overall number of secretory
granules was unchanged (Figures 5I–5K), suggesting that loss
of Nkx6.1 does not affect vesicle formation or stability. In accor-
dance with the observed defect in insulin biosynthesis, our
examination of vesicle morphology revealed a smaller overalln of Nkx6.1Dadultb and control islets with Ad-Glut2 or Ad-b-gal shows that Ad-
lues (n = 3).
m channel activator Bay K8644 and control islets treated with vehicle (n = 3).
n of Nkx6.1Dadultb mice with 8 mg/kg Bay K8644 or control mice injected with
cell proliferation in Nkx6.1Dadultb mice.
GKA (J) or 100 nM insulin (K) for 3 hr and islets from control mice treated with
. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5. Nkx6.1 Is Necessary for Insulin Biosynthesis
(A) qRT-PCR analysis of islets reveals reduced expression of genes involved in insulin biosynthesis inNkx6.1Dadultb compared with control mice at 6 weeks (n = 3).
(B–E) Immunofluorescence staining of pancreata from Nkx6.1Dadultb and control mice at 6 weeks. Dashed lines represent islet area.
(F) qRT-PCR analysis of Nkx6.1Dadultb and control islets from mice at 6 weeks shows no significant difference in Ins1 or Ins2 expression (n = 3).
(G) Proinsulin content normalized to the protein concentration of whole pancreatic lysates (n = 6).
(H) The pancreatic insulin-to-proinsulin ratio is reduced in Nkx6.1Dadultb mice (n = 6).
(I and J) TEM of pancreatic sections reveals smaller vesicle size and an increase in immature vesicles (red arrowheads) in Nkx6.1Dadultb compared with control
mice. Dashed boxes indicate area of magnification in (I’) and (J’). Blue arrowheads point to vesicles containing mature insulin-dense core granules. Insets framed
in red show a representation of a typical immature vesicle, and insets framed in blue show a typical mature vesicle.
(K–M) Quantification of vesicle numbers (K), vesicle diameter (L), and the percentage of mature and immature vesicles (M) in Nkx6.1Dadultb and control mice (n =
10). In (G)–(M), mice were analyzed at 7 weeks. PC1, prohormone convertase 1/3. Data are shown as mean ± SEM for (A) and (F)–(H), and ±SD for (K)–(M). *p <
0.05, **p < 0.01, ***p < 0.001.
See also Figure S5.
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Figure 6. Increased Expression of the Pro-
genitor Marker Ngn3 in Nkx6.1-Deficient
Beta Cells
(A and B) qRT-PCR (A) and western blot analysis
(B) of islets from Nkx6.1Dadultb and control mice at
6 weeks for multiple transcription factor genes (A)
or Ngn3 (B); n = 3.
(C–L) Immunofluorescence staining of pancreata
from Nkx6.1Dadultb and control mice at 6 weeks
(C–F) and 14 weeks (G–L). Dashed lines represent
islet area. Insets are magnifications of selected
areas. Arrowhead in (K) points to a cell coex-
pressing insulin (Ins) and somatostatin (Som).
The scale bar represents 20 mm. Gluc, glucagon;
PP, pancreatic polypeptide. Data are shown as
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.vesicle size in beta cells of Nkx6.1Dadultb mice (Figures 5I0, 5J0,
and 5L). Reduced vesicle size was similarly observed in the
MODY (Ins2Akita) mouse model of impaired insulin biosynthesis
(Wang et al., 1999). In addition to their reduced size, secretory
granules in beta cells of Nkx6.1Dadultb mice exhibited a smaller
halo around the dense core of mature insulin (Figures 5I0 and
5J0, blue arrowheads), a feature that reflects reduced processing
of proinsulin to insulin (Orci et al., 1984). Moreover, the pro-
portion of immature vesicles was significantly increased in
Nkx6.1-deficient beta cells (Figure 5M), representing another
feature of impaired insulin processing. These findings demon-
strate that changes in the expression of insulin biosynthesis-
associated genes after Nkx6.1 deletion manifest as defects in
insulin processing and mature insulin secretory vesicle forma-
tion. Given previous evidence that deletion of Ero1lb and
Slc30a8 in mice perturbs glucose homeostasis (Nicolson et al.,
2009; Zito et al., 2010), these defects in insulin biosynthesis
together with the impaired insulin secretory response are likely
the predominant cause of diabetes in Nkx6.1Dadultb mice.
Nkx6.1 Inactivation Destabilizes Beta Cell Identity
In T2D mouse models of metabolic stress, reduced beta cell
insulin production is associated with a decrease in Nkx6.1,
Pdx1, and NeuroD expression, as well as increased expression
of the pancreatic progenitor cell marker Ngn3 and the pluripo-
tency markers Oct4, Nanog, and L-Myc (Talchai et al., 2012).
Because a subset of metabolically stressed beta cells eventually
adopt other endocrine fates, it has been proposed that beta cell
dedifferentiation followed by conversion into other endocrine
cell types could cause beta cell failure in T2D (Talchai et al.,
2012). Although Nkx6.1 deletion did not affect the expression
of Pdx1, NeuroD, or pluripotency markers (Table S1; Figures
6A, 6C, and 6E), we observed robust induction of Ngn3 expres-
sion in beta cells similar to what has been observed in modelsCell Reports 4, 1262–1275, Sepof metabolic stress (Table S1; Figures
6A, 6B, 6D, and 6F). To investigate
whether the upregulation of Ngn3 is asso-
ciated with destabilization of beta cell
identity, we examined pancreata from
Nkx6.1Dadultb mice at 14 weeks of age
(8 weeks after Nkx6.1 deletion) for coex-pression of insulin with other pancreatic hormones. We did not
observe coexpression of insulin with glucagon or pancreatic
polypeptide in Nkx6.1Dadultb or control islets, but found a signif-
icant number of insulin+ cells coexpressing somatostatin in
Nkx6.1Dadultb mice (Figures 6G–6L). This finding is consistent
with our previous observation of a beta-to-delta cell fate switch
after Nkx6.1 ablation in embryonic beta cells (Schaffer et al.,
2013) and suggests that, although it does not happen immedi-
ately, Nkx6.1 inactivation in adult beta cells causes beta cells
to adopt a delta cell identity over time. In conjunction with our
previous findings, these data strongly suggest that loss of
Nkx6.1 in adult mice destabilizes beta cell identity, eventually
leading to fate conversion of beta into delta cells.
Together, our analysis demonstrates that Nkx6.1 is a critical
regulator of insulin biosynthesis and secretion, as well as pro-
liferative capacity and cell identity in adult beta cells. The severe
beta cell defects observed after Nkx6.1 inactivation suggest
that restoring Nkx6.1 levels could be a therapeutic strategy
in T2D.
DISCUSSION
It is widely recognized that beta cell dysfunction, specifically the
inability of beta cells to properly secrete insulin in response to
high blood glucose levels, is among the earliest clinical features
during progression to T2D (Ferrannini, 2010). The ability to sense
glucose levels and to couple this information to an insulin secre-
tory response is bestowed upon beta cells by specialized trans-
porters and enzymes. Although the mechanisms that underlie
glucose-mediated insulin secretion are fairly well understood, it
has remained unclear which transcriptional regulators initiate
and maintain the expression of genes that enable beta cells to
perform their highly specialized function. In this study, we
show that the transcription factor Nkx6.1 is a master regulatortember 26, 2013 ª2013 The Authors 1271
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Figure 7. Nkx6.1 Function in Adult Beta Cells
Nkx6.1 directly regulates transcription of genes encoding proteins involved in
glucose uptake and metabolism (Glut2 and Pcx) and insulin biosynthesis
(Ero1lb and Slc30a8). Reduced expression of these Nkx6.1 target genes
affects beta cell function in three ways: First, decreased glucose uptake and
metabolism diminishes ATP production, leading to impaired insulin secretion
via the stimulus-secretion coupling pathway. Second, by enabling glucose
uptake through Glut2 regulation, Nkx6.1 indirectly controls beta cell prolifer-
ative capacity. In the absence of Nkx6.1, expression ofCcnd2, which encodes
the critical beta cell mitogen Cyclin D2, is reduced and beta cell proliferation is
decreased. Reconstituting Glut2 expression in Nkx6.1-deficient beta cells
restores Ccnd2 levels and beta cell proliferation. Third, insulin biosynthesis is
severely impaired, leading to reduced production of mature insulin and an
overabundance of immature secretory vesicles. Gck, glucokinase; Glut2,
glucose transporter 2; KATP, ATP-sensitive potassium channel; Pcx, pyruvate
carboxylase.of genes that define the functional beta cell state, a role that
is consistent with its exclusive expression in beta cells of the
adult pancreas.
We show that conditional inactivation ofNkx6.1 in beta cells of
adult mice results in overt diabetes within days of Nkx6.1 abla-
tion. Loss of Nkx6.1 activity had an immediate and dramatic
impact on the expression of genes that give beta cells their
unique ability to synthesize and release insulin in a regulated
fashion. We found that genes involved in insulin biosynthesis
(Slc30a8 and Ero1lb), glucose import (Glut2), and glucose meta-
bolism (Pcx) are direct transcriptional target genes of Nkx6.1. In
addition, Nkx6.1 ablation indirectly affected the expression of
numerous genes that are important for beta cell function and,
interestingly, also beta cell proliferation (Figure 7). The finding
that isletCcnd2 levels and beta cell proliferation were decreased
in Nkx6.1 conditional mutant mice was somewhat surprising, as
several studies have shown that hyperglycemia has a stimulatory
effect on beta cell Ccnd2 expression and self-renewal (Alonso
et al., 2007; Bonner-Weir et al., 1989; Salpeter et al., 2011). We
found that reduced availability of the beta cell mitogen insulin
(Paris et al., 2003) made no apparent contribution to the reduced
proliferative capacity of beta cells after Nkx6.1 ablation. Instead,
our results suggest that the proliferative capacity of Nkx6.1-defi-
cient beta cells is limited by the reduced intracellular availability
of glucose due to loss ofGlut2 expression (Figure 7). These find-1272 Cell Reports 4, 1262–1275, September 26, 2013 ª2013 The Auings demonstrate an intricate link between the beta cell’s ability
to import glucose and its proliferative capacity, which lends
further support to the emerging concept that glucose meta-
bolism plays a critical role in the regulation of beta cell prolifera-
tion (Porat et al., 2011; Salpeter et al., 2010, 2011). Combined
with the finding that Nkx6.1 levels are reduced in T2D models
of metabolic stress (Talchai et al., 2012), our work suggests
that Nkx6.1 acts as a metabolic sensor that modulates both
insulin secretion and proliferative capacity in response to
metabolic stress. By preventing the proliferation of beta cells
that have lost glucose responsiveness, the cell-autonomous
coupling of glucose import to beta cell proliferation might pro-
vide an inherent selection mechanism for healthy beta cells.
Our study also reconciles previously reported, seemingly con-
tradictory findings about the role of Nkx6.1 in beta cell prolifera-
tion. We recently reported that transgenic overexpression of
Nkx6.1 in beta cells of adult mice in vivo had no positive effect
on beta cell proliferation or beta cell mass (Schaffer et al.,
2011). By contrast, virus-mediated expression of Nkx6.1 in
cultured islets had proproliferative activity (Schisler et al.,
2008). A possible explanation for this apparent contradiction is
that in vitro culture of islets compromises Nkx6.1 expression
levels. It is known that once they are removed from their niche
and put into culture, beta cells quickly lose Glut2 expression
and cease to proliferate (Weinberg et al., 2007), indicating that
expression of upstream Glut2 regulators, including Nkx6.1,
could also be compromised. Thus, the observed proproliferative
effect of Nkx6.1 in vitro may be explained by virally expressed
Nkx6.1 restoring reduced Nkx6.1 levels and, in turn, also Glut2
and Ccnd2 levels in cultured islets. By contrast, increasing
Nkx6.1 levels above normal in healthy beta cells in vivo appears
to have no further stimulatory effect on glucose import and beta
cell proliferation.
After Nkx6.1 deletion, we observed an extremely rapid decline
in beta cell insulin content. The loss of insulin was not associated
with beta cell death, revealing a striking similarity between
Nkx6.1-deficient beta cells and ‘‘empty’’ beta cells observed in
mouse models of T2D (Talchai et al., 2012). Furthermore, as
reported under conditions of metabolic stress (Talchai et al.,
2012), we found that reduced Nkx6.1 expression was also
accompanied by derepression of the endocrine progenitor cell
marker Ngn3. Based on the observation that beta cells undergo
fate conversion into non-beta endocrine cell types in T2Dmodels
(Talchai et al., 2012), the loss of beta cell features and gain of
Ngn3 expression has been proposed to render beta cells plastic
and more prone to changing their identity.
Consistent with this notion, we observed that a subset of
Nkx6.1-deficient beta cells ectopically expressed somatostatin
8 weeks after Nkx6.1 deletion. Previously, we showed with line-
age tracing studies that Nkx6.1 deletion in embryonic beta cells
leads to a rapid beta-to-delta cell fate switch (Schaffer et al.,
2013). However, conversion of beta cells into other non-beta
endocrine cell types was not observed after Nkx6.1 inactivation
in embryonic beta cells. Similarly, after Nkx6.1 deletion in adult
beta cells, we observed coexpression of insulin exclusively with
somatostatin and no other pancreatic hormones. Thus, loss of
Nkx6.1 leads to selective derepression of delta cell genes in
both embryonic and adult beta cells. However, fate conversionthors
is more complete and occurs more rapidly when Nkx6.1 is inac-
tivated in immature beta cells. Therefore, a sequential loss of beta
cell traits preceding the adoption of alternative endocrine cell
fates seen after adult Nkx6.1 inactivation closely mirrors the
gradual loss of functional beta cell mass observed in T2Dmodels
(Talchai et al., 2012).
Our study provides support for an evolving concept that tran-
scription factors, such as Nkx6.1 and FoxO1 (Talchai et al.,
2012), are critical for maintaining beta cells in their differentiated
state. A key question that requires further exploration is whether
a destabilized beta cell state is observed in humans and possibly
contributes to the pathogenesis of T2D. The observation that
NKX6.1 expression is decreased in beta cells from humans
with T2D (Guo et al., 2013) suggests that findings in rodent
models might indeed be relevant to human disease. Future
studies will need to explore which aspects of the rodent pheno-
type are also found in humans and how loss of beta cell features
relates to disease progression. Such knowledge could identify a
window for therapeutic intervention during which the functional
beta cell state could be restored before beta cells convert into
other endocrine cell types.
EXPERIMENTAL PROCEDURES
Mouse Strains
The followingmouse strains were utilized in this study:Pdx1CreERTM (Gu et al.,
2002), Nkx6.1+/ (Sander et al., 2000), and Nkx6.1flox (Schaffer et al., 2013). All
animals carrying the Nkx6.1flox allele were maintained on a mixed 129Sv/
C57Bl6/J genetic background. Unless otherwise stated in the text, male
mice were used for the experiments. Tamoxifen (Sigma) was dissolved in
corn oil at 20 mg/ml, and 2 mg was injected subcutaneously four times over
a 2-week period. All animal experiments were approved by the Institutional
Animal Care and Use Committees of the University of California, San Diego.
Tissue Preparation and Immunohistochemistry
Tissue preparation, immunofluorescence staining, TUNEL assays, and
morphometry were performed as previously described (Schaffer et al., 2010,
2013). A description of the antibodies used (Tables S4 and S5) and detailed
methods are provided in the Extended Experimental Procedures.
Microscopy and Image Analysis
All immunofluorescent images were acquired using a Zeiss AxioOberver.Z1
microscope (Carl Zeiss) with the Zeiss ApoTome module and processed in
Zeiss AxioVision Release 4.8 and Adobe Photoshop CS5.1. Only brightness
and contrast was adjusted in images in accordance with the Journal of Cell
Biology figure manipulation guidelines.
Glucose Tolerance Tests, GSIS Assays, and Insulin and Proinsulin
Measurements
Glucose tolerance tests, GSIS assays, and insulin measurements were per-
formed as previously described (Schaffer et al., 2011). Proinsulin measure-
ments were performed on whole pancreatic lysates using a mouse proinsulin
ELISA (ALPCO). Details are described in the Extended Experimental
Procedures.
Islet Isolation and Culture
Islet isolations were performed as previously described (Schaffer et al., 2011)
with Liberase TL (Roche). For incubation of islets with chemical com-
pounds, RPMI supplemented with 2.7 mM glucose and 1% BSA was used.
Nkx6.1Dadultb islets were incubated with 100 nM recombinant insulin (Sigma),
60 mM ± Bay K8644 (Sigma), or 10 mM glucokinase activator (GKA; EMD Cal-
biochem), and control islets were incubated with DMSO (ATCC) for 3 hr. For
infection of islets with Ad-Glut2 and Ad-b-gal, the islets were dispersed andCell Replated before infection as described previously (Fiaschi-Taesch et al., 2009).
Further details are provided in the Extended Experimental Procedures.
Microarray and qRT-PCR
RNA was isolated from islets obtained from six littermate control and six
Nkx6.1Dadultb mice. Islets from two mice of identical genotypes were pooled
to generate three independent cDNA probes per genotype for array hybridiza-
tion. Labeled cDNA was hybridized to whole-mouse gene-expression G2519F
microarrays (Agilent Technologies). A detailed description of the microarray
and qRT-PCR analyses and a list of the primer sequences (Table S6) can be
found in the Extended Experimental Procedures.
ChIP-Seq
ChIP was performed as previously described (Schaffer et al., 2013) with rabbit
anti-Nkx6.1 antiserum (1:250) on sheared chromatin obtained from 10,000
islet equivalents (1,000 cells per islet) isolated from C57BL/6J mice. ChIP-
seq libraries were prepared according to Illumina’s instructions (http://www.
illumina.com). Sequencing was performed on an Illumina/Solexa Genome
Analyzer II in accordance with the manufacturer’s protocols. Data analysis
was performed using Hypergeometric Optimization of Motif EnRichment
(HOMER) (Heinz et al., 2010). Peak annotation and de novo motif analysis
were performed using HOMER, and venn diagrams were generated using
BioVenn (Hulsen et al., 2008). See the Extended Experimental Procedures
for details.
Statistics
Unless otherwise stated, all values are shown as mean ± SEM; p values were
calculated using an unpaired Student’s t test in Microsoft Excel, and hyper-
geometric distribution was determined using R; p < 0.05 was considered
significant.
ACCESSION NUMBERS
The NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) accession number for the
microarray data set reported in this paper is GSE40470. The GEO accession
number for the ChIP-seq data set reported in this paper is GSE40975.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and six tables and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2013.08.010.
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